AtriCure

AtriCure argues that surgical ablation provides durable, transmural lesions that catheter point-by-point ablation often fails to achieve, leading to lower long-term recurrence rates. The firm's funded clinical trials, including DEEP AF and CONVERGE, are designed to produce head-to-head evidence comparing hybrid surgical approaches to endocardial catheter ablation alone. This evidence base supports reimbursement expansion and guideline inclusion.

AtriCure's revenue is predominantly capital equipment and single-use disposable sales. Recurring revenue comes from repeat procedures using disposable ablation clamps, pens, and AtriClip devices — each cardiac surgery case typically consumes one clamp plus ancillary disposables. The firm does not operate a software-as-a-service or monitoring subscription model.

The 2018 SentreHEART acquisition for $300 million brought the LARIAT suture-delivery system and a pipeline of left atrial appendage closure technologies into AtriCure's portfolio. This moved the firm beyond ablation into structural heart interventions, directly competing with Boston Scientific's Watchman device. The deal also added a dedicated electrophysiologist call point alongside AtriCure's traditional cardiothoracic surgeon relationships.

AtriCure holds FDA PMA approvals for the Isolator Synergy ablation system for treatment of persistent and long-standing persistent atrial fibrillation during concomitant cardiac surgery, and 510(k) clearances for the EPi-Sense and AtriClip lines. The CE Mark permits broader use in Europe. The firm's label expansions in the United States — from concomitant-only to hybrid stand-alone procedures — have been the primary driver of revenue growth.

Medtronic competes with the Cardioblate ablation system and CryoFlex products. Johnson & Johnson's Biosense Webster division dominates the catheter ablation market, which competes indirectly. Boston Scientific's Watchman device competes directly in left atrial appendage closure. AtriCure's niche is the hybrid surgical-electrophysiology convergent procedure, which no single competitor replicates.

AtriCure allocates approximately 15–20% of annual revenue to research and development, funding internal device iterations and clinical trials. The firm has completed several tuck-in acquisitions — including Estech (2013), nContact (2015), and SentreHEART (2018) — to acquire complementary energy modalities and anatomical targets. The balance-sheet strategy prioritizes de novo clinical evidence over large-scale M&A.

AtriCure distributes directly in the United States and through distributor partnerships in more than 60 countries. Western Europe and Japan represent the largest ex-US markets, with particular strength in Germany, the United Kingdom, and the Netherlands. The firm has invested in direct sales teams in select European markets, though most international revenue remains distributor-mediated.